Recently approved antibody therapies targeting inhibitory ICI proteins such as cytotoxic T lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1) and its ligand (PD-L1) have demonstrated valuable clinical benefit in the treatment of cancer [11]. Here, CTLA4 is linked to cancer.